Global Leading Market Research Publisher QYResearch announces the release of its latest report “Myocardial Infarction Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Myocardial Infarction Drug market, including market size, share, demand, industry development status, and forecasts for the next few years. For cardiovascular franchise leaders, hospital pharmacy directors, and health system strategists, the management of acute myocardial infarction (MI) is undergoing its most significant therapeutic transformation in a decade. The 2025 ACC/AHA Guideline for the Management of Patients with Acute Coronary Syndromes, published in JACC and Circulation, has fundamentally restructured the evidence base for dual antiplatelet therapy (DAPT), non-statin lipid-lowering, and revascularization strategies . Meanwhile, novel antibody drugs targeting ischemia-reperfusion injury and a new generation of PCSK9 inhibitors are reshaping the innovation frontier. This market research values the global Myocardial Infarction Drug market at USD 2,400 million in 2025, projecting expansion to USD 3,870 million by 2032 at a compound annual growth rate (CAGR) of 7.2%. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6606328/myocardial-infarction-drug Product Definition and Therapeutic Architecture Myocardial Infarction Drug encompasses pharmaceutical products used for the treatment of acute myocardial infarction—a severe ischemic cardiac event—and for the prevention of its recurrence. Myocardial infarction, commonly known as a heart attack, is caused by atherosclerotic plaque rupture in the coronary arteries leading to thrombus formation, which sharply interrupts myocardial blood supply and results in ischemic necrosis of cardiomyocytes. The 2025 guidelines jointly issued by the American College of Cardiology and the American Heart Association systematically standardized the management of acute coronary syndromes . Myocardial Infarction Drugs are divided into two major categories based on timing of action: acute-phase reperfusion therapies and long-term secondary prevention drugs. The core goal of acute-phase treatment is to restore myocardial blood flow as quickly as possible, with thrombolytic drugs dissolving thrombi by activating the fibrinolytic system and antiplatelet drugs inhibiting platelet aggregation to prevent new thrombus formation. Long-term secondary prevention drugs include statin lipid-lowering drugs to stabilize plaques, beta-blockers to reduce myocardial oxygen consumption, and angiotensin-converting enzyme inhibitors to improve ventricular remodeling. From an industrial attribute perspective, these drugs sit at the intersection of cardiovascular pharmacology, thrombosis and hemostasis, and emergency medicine. Their core value lies in rapidly opening infarct-related arteries to salvage dying myocardium, reducing acute-phase mortality, and improving long-term prognosis. Market Analysis: Guideline-Driven Transformation and Innovation Catalysts The continuously rising global prevalence of coronary heart disease directly drives clinical demand for anti-MI drugs. The acceleration of population aging, with the high incidence of cardiovascular diseases in the elderly population, further expands the medication population. The 2025 ACC/AHA guideline introduces major practice-changing recommendations that are reshaping prescribing patterns globally: for ACS patients undergoing PCI who are not at high bleeding risk, prasugrel or ticagrelor is now recommended in preference to clopidogrel (Class 1), and DAPT should be administered for at least 12 months as the default strategy . On the lipid-lowering frontier, the guideline now provides a Class 1 recommendation for adding a non-statin lipid-lowering agent—such as ezetimibe, a PCSK9 inhibitor, or bempedoic acid—in ACS patients already on maximally tolerated statin therapy with LDL-C ≥70 mg/dL . This represents a significant expansion of the addressable market for novel lipid-lowering therapies. The VESALIUS-CV trial, published in NEJM in November 2025, demonstrated that PCSK9 inhibition with evolocumab reduced the risk of 3-point MACE by 25% compared with placebo in patients without a previous MI or stroke, further validating the clinical value of intensive lipid lowering earlier in the atherosclerotic disease process . A landmark development reshaping the innovation frontier is the emergence of antibody drugs targeting myocardial ischemia-reperfusion injury. SGC001, a first-in-class antibody developed by Shunjing Pharmaceutical (a subsidiary of Hotgen Biotech), received dual IND approval from the US FDA and China's NMPA in 2024, followed by FDA Fast Track designation in 2025 . In October 2025, the Phase Ib clinical study reported positive preliminary results, demonstrating that SGC001 effectively improved ischemic myocardial microcirculation in acute anterior STEMI patients undergoing PCI, with the medium and high-dose groups showing significantly reduced myocardial infarct size. In January 2026, at the 43rd J.P. Morgan Healthcare Conference, Shunjing announced the formal initiation of Phase II clinical trials for SGC001—the world's first antibody therapy for acute MI to enter late-stage development . Comparative Analysis: Regional Treatment Paradigm Divergence A critical analytical observation from this market research concerns significant heterogeneity in antiplatelet and lipid-lowering treatment strategies across global regions—a divergence with profound implications for market share dynamics. The 2025 ACC/AHA guideline reflects ongoing debate regarding P2Y12 inhibitor selection: while prasugrel and ticagrelor are both Class 1 recommendations for PCI-treated ACS patients, the guideline does not endorse one over the other, citing uncertainty regarding the generalizability of findings from a single open-label study comparing the two agents . The European Society of Cardiology guideline, by contrast, favors prasugrel (Class 2a) over ticagrelor . Asia-Pacific markets exhibit particularly pronounced divergence. Japan has adopted a low-dose prasugrel regimen distinct from Western dosing protocols, with widespread use of intravascular imaging-guided therapy. China uses clopidogrel and ticagrelor, but prasugrel remains unavailable in the market—creating a significant treatment gap relative to guideline recommendations. India faces urban-rural healthcare resource disparities, with continued reliance on thrombolytic therapy in remote areas and clopidogrel remaining the mainstream antiplatelet choice due to price accessibility, while ticagrelor use increases only in high-income urban areas . The INCLINE-AMI trial—a multicenter randomized controlled study with 2,442 patients across 80 centers in China, enrolling from September 2025 to August 2027—is evaluating whether early PCSK9 inhibitor administration within 24 hours of AMI perioperative PCI can safely reduce LDL-C, control systemic inflammation, and improve MACE outcomes, potentially establishing a new standard of care for Asian populations . Market Challenges: Supply Concentration, Pricing, and Generic Erosion Myocardial Infarction Drugs face the severe challenge of concentrated supply of core active pharmaceutical ingredients (APIs) and price monopoly risks. China's State Administration for Market Regulation imposed a fine of RMB 285 million on Grand Pharmaceutical for monopolizing the norepinephrine API, which is used to produce acute MI emergency injections. This monopolistic behavior led to increased formulation prices and frequent shortages, affecting patient access to medication—a regulatory action that underscores the systemic vulnerability of concentrated API supply chains for essential cardiac rescue drugs. The high pricing of some innovative drugs poses pressure on healthcare payment capacity. In the United States, ticagrelor remains patented and more expensive than generic prasugrel, and cost may influence drug selection in health systems with constrained pharmacy budgets . Generic competition intensifies after patent expiration, eroding the market share of branded drugs. The de-escalation strategy—switching from ticagrelor or prasugrel to clopidogrel after one month—has received a Class 2b recommendation in the 2025 guideline specifically to address bleeding risk, adverse effects, or cost-related concerns, reflecting the pragmatic reality that economic considerations influence clinical decision-making . Innovation Pipeline and Future Outlook The downstream demand landscape reveals several high-growth segments. The acute MI emergency setting shows the most urgent demand for antiplatelet drugs, with DAPT having become the standard regimen following PCI. The demand for novel lipid-lowering drugs continues to grow in the secondary prevention field, with the 2025 guideline now recommending non-statin agents for patients above LDL-C thresholds despite maximally tolerated statins . Emerging evidence on PCSK9 inhibition reducing post-MI myocardial inflammation—as demonstrated by the EVACS trial showing evolocumab significantly reduced myocardial inflammation assessed by FDG-PET imaging, with higher inflammation linked to adverse cardiac remodeling at 6 months—further strengthens the clinical case for early intensive lipid lowering . Beyond small molecules and antibodies, gene therapy and cell therapy are converging with sustained-release delivery technologies for cardiac applications. Encapsulated cell therapy implants capable of secreting therapeutic proteins over extended periods represent a frontier development that could reshape long-term secondary prevention paradigms. Competitive Landscape The Myocardial Infarction Drug market features a competitive landscape spanning global pharmaceutical leaders and regional champions. Key participants include: Novartis, Pfizer, Johnson & Johnson, Merck, AstraZeneca, Roche, Bayer, Daiichi Sankyo, CSL, Sino Biopharmaceutical, Shanghai Pharma, Lee's Pharmaceutical, and Fosun Pharma. The market is segmented by type into Antiplatelet Drug, Anticoagulant Drug, Thrombolytic Drug, Lipid Lowering Drug, and Heart Rate Control Drug, and by application across Cardiac Emergency and Cardiac Long-Term Therapy. As guideline-directed medical therapy continues to evolve toward more personalized approaches balancing ischemic and bleeding risks, and as novel antibody and PCSK9-targeting therapies expand the innovation frontier, the MI drug market is positioned for sustained growth through 2032. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp